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Andrew H. Beck*
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Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, United States of America
* abeck2@bidmc.harvard.edu
Cancer is a heterogeneous disease, which is comprised of a collection of diseases traditionally
categorized by tissue type of origin. A distinct set of etiologic causes, treatments, and prognoses
are associated with different cancers, and even within a given tissue type, cancer shows signifi-
cant variability in molecular and clinical features across patients. This interpatient heterogene-
ity is a major rationale for large-scale research efforts (such as The Cancer Genome Atlas
[TCGA] and the International Cancer Genome Consortium [ICGC]) to comprehensively pro-
file the molecular landscape of patient cancer samples across all major cancers [1,2]. These ef-
forts have been bolstered by the recent development of new genomic [3] and computational [4]
technologies to enable increasingly detailed and comprehensive analyses of the molecular land-
scape of solid cancers. It is hoped that the comprehensive molecular characterization of large
sets of cancer samples will lead to the identification of new therapeutic targets and the develop-
ment of improved personalized therapies for cancer patients.
A major challenge in cancer therapy is the development of resistance to molecularly targeted
therapies. Although targeted therapies may show initial benefit in the subset of patients carry-
ing a targeted molecular alteration, most patients will nevertheless go on to develop resistance
for most advanced solid cancers. Identifying and overcoming drug resistance represents one of
the most significant challenges facing cancer researchers today [5]. It is increasingly recognized
that cancer is not only a heterogeneous disease across patients but also a heterogeneous disease
within individual patients, with different regions of a tumor showing different molecular fea-
tures at the DNA, RNA, and protein levels [6–9]. This intratumoral molecular heterogeneity is
hypothesized to be a major cause of drug resistance and treatment failure in cancer [10]. How-
ever, the clinical significance of intratumoral molecular heterogeneity is not yet well-defined,
and assessment of intratumoral molecular heterogeneity is not currently used in clinical cancer
medicine for assessing disease prognosis or guiding therapy. Two recent research articles pub-
lished in PLOS Medicine show the potential clinical utility of measuring intratumoral genetic
heterogeneity in clinical cancer samples.
In one, James Brenton, Florian Markowetz, and colleagues applied the Minimum Event Dis-
tance for Intra-tumour Copy-number Comparisons (MEDICC) algorithm they recently devel-
oped for phylogenetic quantification of intratumoral genetic heterogeneity from multiregion
DNA copy number profiling data [11] to predict treatment resistance in high-grade serous
ovarian cancer [12]. Their analysis suggests that multiregion tumor sampling, DNA copy num-
ber profiling, and quantification of intratumoral genetic heterogeneity with the MEDICC algo-
rithm could be a useful approach for predicting patient survival in ovarian cancer, in which
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higher levels of heterogeneity associated with decreased survival. This study provides data to
support the long-standing hypothesis regarding treatment resistance and intratumoral genetic
heterogeneity [10]. Although these results are promising, the developed approach requires
sampling multiple distinct regions of tumor, which would be more expensive and complex
than molecular profiling from a single tissue sample. It is not yet known how much tumor sam-
pling will be required to adequately quantify intratumoral heterogeneity in the clinic or if mea-
suring intratumoral heterogeneity from multiple tumor samples will outperform other
molecular approaches (e.g., prognostic expression signatures [13,14]) for predicting response
to therapy in ovarian cancer. These are important research questions that will need to be an-
swered prior to clinical translation.
The second study comes from James Rocco and colleagues [15]. Previously, these investiga-
tors used a publicly available data set of whole exome sequencing data in head and neck squa-
mous cell carcinoma (HNSCC) from Stransky et al. [16] to develop a simple quantitative
measure of intratumoral heterogeneity (mutant-allele tumor heterogeneity [MATH]) and
showed that MATH scores were higher in poor outcome classes of HNSCC [17]. In the current
study, the authors used publicly available whole exome sequencing data provided by TCGA
and showed that the MATH score is associated with prognosis in HNSCC and contributes ad-
ditional prognostic information beyond that provided by traditional clinical and molecular fea-
tures. Since the MATH score can be computed from whole exome sequencing data obtained
from a single tumor sample (which is a data type that can be obtained from formalin-fixed,
paraffin-embedded tumor tissue, as is routinely collected in pathology laboratories [18]), this
approach may be more easily translated into clinical use, as compared with approaches requir-
ing multiregion sampling and more complex computational algorithms for the assessment of
intratumoral heterogeneity. Nonetheless, establishing the utility of the MATH score as an ef-
fective prognostic and/or predictive biomarker in HNSCC will require additional studies of the
MATH score on well-controlled clinical cohorts comprised of homogeneously treated patients
with tumors at specific head and neck anatomic locations. It is important to note that the devel-
opment and application of MATH for assessing prognosis in HNSCC was based entirely on
the analysis of publically available clinically annotated whole exome sequencing data, which
demonstrates the value in making these data open to the community.
The continuing generation of high-quality, open-access Omics data sets from large populations
of cancer patients will be critically important to enable the development of computational meth-
ods to translate knowledge of cancer heterogeneity into new diagnostics and improved clinical
outcomes for cancer patients. As one step towards this goal, the DREAM (Dialogue for Reverse
Engineering Assessments andMethods) consortiumwill use open innovation crowd sourcing to
identify top-performing computational methods for inferring genetic heterogeneity from next-
generation sequencing data provided by a large multi-institutional community of cancer genomics
projects, including the ICGC and TCGA [19]. If successful, this open innovation competition may
identify a set of best-in-class methods for measuring intratumoral genetic heterogeneity in cancer.
In parallel with these advances in computational methods for inferring intratumoral hetero-
geneity from genomics data, genomics technologies for measuring intratumoral heterogeneity
at increasingly fine levels of granularity continue to improve. For example, recent advances in
single-cell sequencing of DNA have provided detailed portraits of intratumoral genetic heteroge-
neity and clonal evolution in cancer [20,21], and recent advances in single-cell RNA sequencing
[22], in situ RNA sequencing [23,24], and highly multiplexed next-generation immunohis-
tochemistry [25–28] enable characterization of intratumoral heterogeneity in gene expression at
a single cell level with subcellular resolution. Thus, there are now many options—both molecular
and computational—for measuring and analyzing intratumoral molecular heterogeneity from
clinical cancer samples.
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Establishing the clinical utility of these new approaches for measuring intratumoral molecular
heterogeneity will require applying these methods to large sets of archival tumor samples from
randomized trials of cancer therapeutics [29] and high-quality prospective observational studies
[30]. To maximize the value of the data that would be produced from such an undertaking, it is
critical that infrastructure be created and supported to enable sharing of the Omics and clinical
data with a large community of cancer researchers and data scientists. Ensuring open access to
high-quality datasets will ensure that the largest possible community of researchers is able to ad-
dress the most important problems in cancer medicine today. And in generating and sharing
these data widely, we will massively increase our chances of effectively translating knowledge of
intratumoral heterogeneity into meaningful advances for cancer patients.
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